Antisense Oligonucleotide Service

Creative Biogene is one of the leading biotechnology companies which has the expertise and ability in providing antisense oligonucleotide service for customers worldwide. Creative Biogene's sophisticated equipments, advanced technologies and highly experienced staffs are available to provide you with the comprehensive antisense oligonucleotide service, including antisense oligonucleotide synthesis, ASO in vitro screening service and ASO in vivo testing service. Creative Biogene’s goal is to provide you with the most affordable, high-quality antisense oligonucleotide service to ensure your satisfaction in a timely and professional manner.

Antisense technology is a universal approach for the inhibition of gene expression in a sequence-specific manner. Since the discovery that oligodeoxynucleotides can act as antisense agents that inhibit viral replication in cell culture, antisense technology has been used in knockdown experiments, target validation, drug therapy, and other applications. In antisense technology, antisense oligonucleotide represents an excellent tool to inhibit gene expression levels both in vitro and in vivo. Antisense oligonucleotides (ASOs) are 15–25 nt DNA sequences designed to bind complementary RNA targets, ultimately facilitating their degradation. The discovery of antisense oligonucleotide introduced a new approach to the development of drug therapeutics, offers the potential to develop highly selective and less toxic drugs.

In past decade, ASOs have been researched as potential drugs for diseases such as cancers, diabetes, amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, spinal muscular atrophy, and diseases such as asthma, arthritis and pouchitis with an inflammatory component. Several antisense drugs have been approved by the U.S. Food and Drug Administration: fomivirsen as a treatment for cytomegalovirus retinitis, mipomersen for homozygous familial hypercholesterolemia, eteplirsen for Duchenne muscular dystrophy, nusinersen for spinal muscular atrophy, and Inotersen for hereditary transthyretin amyloidosis (hATTR). ASOs technology provided an oligonucleotide-based approach to cure diseases caused by expression of deleterious genes.